4yr
The effect of empagliflozin on p wave peak time and other p wave parameters in patients with diabetes mellitus
Source : https://onlinelibrary.wiley.com/doi/10.1111/pace.14463
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as https://doi.org/10.1111/pace.14463 Accepted Articles
Conclusion: We found shortening of PWPT, PWdis, and PWD as reflections of improvements in LA volume and LV diastolic function on ECG after empagliflozin treatment.
Share
• Source: Pacing and Clinical Electrophysiology
• Conclusions/Relevance: “We found shortening of PWPT, PWdis, and PWD as reflections of improvements in LA volume and LV diastolic function on ECG after empagliflozin treatment.”
• In the current study, 53 received electrocardiographic and echocardiographic evaluations at baseline and at 3 months.
• Empagliflozin decreases hospitalizations and death, but the mechanism remains to be elucidated. Improved left ventricular diastolic function and a decrease in filling pressure could play a role, per ECG. Consequently, the authors assessed the effect of empagliflozin on P wave parameters in type 2 diabetes mellitus patients without heart failure.